积雪草甙对乳腺癌MCF-7细胞凋亡及VEGF、bFGF蛋白表达水平的影响

目的:探讨积雪草甙对乳腺癌MCF-7细胞凋亡及VEGF、bFGF蛋白表达水平的影响。方法:选取人乳腺癌细胞MCF-7细胞系进行体外培养后,根据是否进行积雪草甙干预而分为两组,应用积雪草苷进行干预后,HE染色后用光学显微镜法观察细胞形态学变化,干预后的24h、48h以及72h时,应用TUNEL技术对对细胞凋亡情况进行检测,同时应用免疫荧光法检测血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)的表达。结果:(1)与对照组相比较,积雪草甙干预的乳腺癌MCF-7细胞出现空泡、胞质外溢以及胞核皱缩等细胞凋亡现象,大量癌MCF-7细胞发生破碎死亡;(2)TUNEL技术法检测结果证实积雪草甙能够提高人乳腺癌MCF-7细胞凋亡率,与对照组比较差异具有统计学意义(P0.05),且呈时间依赖性;(3)积雪草甙干预的MCF-7细胞VEGF阳性表达和bFGF阳性表达显著低于对照组,差异具有统计学意义(P0.05),积雪草甙的抑制作用且呈时间依赖性。结论:积雪草甙不仅能够促进乳腺癌MCF-7细胞凋亡,而且能够降低VEGF和bFGF表达。     

抑制c-FLIP基因促进TRAIL诱导的乳腺癌细胞凋亡(英文)

目的:探讨抑制c-FLIP的表达对TRAIL诱导乳腺癌细胞MCF-7凋亡的影响。方法:重组腺病毒Ad-c-FLIP-siRNA和Ad-sTRAIL单独及联合感染对TRAIL耐药的乳腺癌细胞MCF-7,应用实时荧光定量聚合酶链反应(Real-time PCR)检测病毒感染后各组细胞内c-FLIP和TRAIL的mRNA表达变化;MTT法和结晶紫染色法检测MCF-7细胞活性,Hoechst 33258荧光染色检测各组细胞的凋亡情况。结果:与阴性对照组比较,c-FLIP-siRNA组和c-FLIP-siRNA+TRAIL组c-FLIP的mRNA相对表达量分别是(0.32±0.16)和(0.39±0.48)倍;TRAIL组和c-FLIP-siRNA+TRAIL组TRAIL的mRNA相对表达量分别是(96.21±1.54)和(87.33±1.66)倍;TRAIL组、c-FLIP-siRNA组及c-FLIP-siRNA+TRAIL组的抑制率(%)分别为(60.27±1.25)、(11.34±1.74)及(74.91±2.12)。对比阴性对照组的凋亡率(3.12±1.54),TRAIL组(12.79±2.46)和c-FLIP-siRNA+TRAIL组(25.50±3.17)组的凋亡率明显增高(P0.05),c-FLIP-siRNA组(6.85±2.82)的凋亡率变化不明显,差异无统计学意义(P0.05)。结论:siRNA抑制c-FLIP基因的表达能显著促进TRAIL对乳腺癌细胞MCF-7凋亡的诱导作用。     

miR-149-5p靶向DCLK1基因对乳腺癌细胞MCF-7/DDP顺铂耐药的影响

[目的]探讨miR-149-5p靶向双皮质素样激酶1(DCLK1)基因对乳腺癌细胞MCF-7/DDP顺铂耐药的影响。[方法]构建DDP耐药乳腺癌MCF-7细胞,然后按细胞转染质粒的不同分入对照组(不转染质粒)、空载组(转染空载质粒3.1)、miRNA-149-5p组(转染miRNA-149-5p-AH质粒)。采用CCK-8法检测细胞存活率,划痕实验检测细胞迁移力,流式细胞术检测细胞凋亡率,实时荧光定量PCR检测细胞miRNA-149-5p和DCLK1 mRNA水平,Western Bloting检测细胞DCLK1蛋白表达水平。[结果] miRNA-149-5p组乳腺癌MCF-7/DDP细胞miRNA-149-5p水平、细胞凋亡率显著高于对照组和空载组,DCLK1 mRNA和蛋白水平、细胞存活率和细胞迁移率显著低于对照组和空载组,差异均有统计学意义(P<0.05)。空载组和对照组miRNA-149-5p水平、细胞凋亡率、DCLK1 mRNA和蛋白表达、细胞存活率和细胞迁移率比较差异均无统计学意义(P>0.05)。[结论]过表达miRNA-149-5p可减弱乳腺癌MCF-7/D...     

SAHA与顺铂联合用药对骨肉瘤细胞增殖、凋亡和迁移的影响

该文研究了组蛋白去乙酰化酶抑制剂SAHA(suberoylanilide hydroxamic acid)联合顺铂(cisplatin,DDP)对骨肉瘤细胞的作用。骨肉瘤143B细胞分别经不同浓度的SAHA、DDP、SAHA+DDP作用48 h。利用倒置显微镜观察细胞形态学变化;分别采用MTT法、流式细胞术、细胞划痕实验、克隆形成实验检测SAHA、DDP及二者联用对143B细胞活力、细胞凋亡、细胞迁移和集落形成能力的影响。利用Western blot检测143B细胞中cleaved-Caspase-8、cleaved-PARP蛋白表达水平。结果显示,SAHA+DDP组143B细胞大量坏死,抑制细胞增殖的现象明显高于单药组;中低剂量SAHA与DDP联用表现为协同作用,而较高剂量的联用表现为单纯相加作用;SAHA+DDP组较单药组细胞早期凋亡率增加、迁移率明显降低,且SAHA+DDP组的细胞集落形成能力明显降低;SAHA+DDP组能够促进cleaved-Caspase-8、cleaved-PARP的蛋白表达。以上结果表明,SAHA联合顺铂对骨肉瘤细胞143B细胞有协同增敏作用,能够明显抑制其增殖和迁移并促进其凋亡。     

ILP-2表达上调减轻双氧水诱导的人MCF-7细胞株凋亡

为探讨乳腺癌细胞生长中凋亡抑制蛋白样蛋白2(ILP-2)对活性氧(ROS)毒性的拮抗作用,该研究用不同浓度双氧水(H_2O_2)对人乳腺癌细胞MCF-7进行氧化应激造模, 2′,7′-二氯荧光黄双乙酸盐探针法(DCFH-DA)检测乳腺癌细胞中活性氧变化,蛋白质印记法检测siRNA干扰效率及干扰后乳腺癌细胞ILP-2的表达,噻唑蓝(MTT)法检测siRNA转染及双氧水处理后乳腺癌细胞的增殖活性,划痕试验分析siRNA转染及双氧水处理对乳腺癌细胞迁移的影响,吖啶橙/溴化乙锭双荧光染色法(AO-EB)检测si RNA转染及双氧水处理对乳腺癌细胞凋亡的影响。结果显示, 200μmol/L双氧水显著诱导MCF-7中活性氧的产生。蛋白质印迹法结果显示, siRNA-5干扰效率较高;双氧水+siRNA-5组ILP-2表达高于双氧水+siRNA阴性对照组。双氧水处理细胞24、48和72 h后, MTT结果显示,细胞存活率明显低于空白对照组,双氧水+siRNA-5组细胞存活率高于双氧水+siRNA阴性对照组;划痕实验结果显示,细胞迁移率低于空白对照组,双氧水+siRNA-5组迁移率高于双氧水+siRNA阴性对照组; AO-EB结果显示,与空白对照组相比,双氧水组细胞凋亡率显著升高,双氧水+siRNA-5组细胞凋亡率低于双氧水+siRNA阴性对照组。以上结果表明,凋亡抑制蛋白ILP-2拮抗活性氧对乳腺癌细胞MCF-7的细胞毒性,促进细胞增殖。     

格列卫与多西紫杉醇联合对人乳腺癌细胞株MCF-7及其裸鼠移植瘤的作用

目的：探讨分子靶向药物格列卫与多西紫杉醇联合对人乳腺癌细胞株MCF-7的凋亡及其裸鼠皮下移植瘤生长的影响。方法：采用流式细胞检测仪检测MCF-7细胞在格列卫与多西紫杉醇单独处理及共同处理条件下的凋亡率;建立人乳腺癌细胞株MCF-7裸鼠皮下移植瘤模型,观察格列卫与多西紫杉醇单独治疗组及联合治疗组移植瘤的生长,计算抑瘤率。结果：MCF-7细胞在格列卫与多西紫杉醇共同处理条件下的凋亡率（50.86%）远高于多西紫杉醇单独处理（22.06%）及同剂量格列卫组单独处理（8.13%）条件下的凋亡率;高剂量多西紫杉醇与格列卫联合组肿瘤质量与单独多西紫杉醇组比较,差异虽然没有显著性,但联合组抑瘤率高达99.55%,高于多西紫杉醇组（97.43%）,q值为1.014;中剂量多西紫杉醇与格列卫联合组肿瘤质量与单独多西紫杉醇组比较,差异有高度显著性,联合组抑瘤率达96.53%,高于多西紫杉醇组（92.01%）,q值为1.02;低剂量多西紫杉醇与格列卫联合组肿瘤质量与单独多西紫杉醇组比较,差异有高度显著性,联合组抑瘤率达68.20%,高于多西紫杉醇组（58.40%）,q值为1.004。结论：格列卫与凋亡诱导剂多西紫杉醇共同处理MCF—7细胞能达到协同诱导凋亡的效果;高、中、低剂量的多西紫杉醇与格列卫联合对人乳腺癌细胞株MCF-7裸鼠移植瘤增殖的抑制具有相加作用。     

抑制c-FLIP基因促进TRAIL诱导的乳腺癌细胞凋亡

目的：探讨抑制c-FLIP的表达对TRAIL诱导乳腺癌细胞MCF-7凋亡的影响。方法：重组腺病毒Ad-c-FLIP-siRNA和Ad-sTRAIL单独及联合感染对TRAIL耐药的乳腺癌细胞MCF-7,应用实时荧光定量聚合酶链反应（Real-time PCR）检测病毒感染后各组细胞内c-FLIP和TRAIL的mRNA表达变化;MTT法和结晶紫染色法检测MCF-7细胞活性,Hoechst 33258荧光染色检测各组细胞的凋亡情况。结果：与阴性对照组比较,c-FLIP-siRNA组和c-FLIP-siRNA＋TRAIL组c-FLIP的mRNA相对表达量分别是（0.32±0.16）和（0.39±0.48）倍;TRAIL组和c-FLIP-siRNA＋TRAIL组TRAIL的mRNA相对表达量分别是（96.21±1.54）和（87.33±1.66）倍;TRAIL组、c-FLIP-siRNA组及c-FLIP-siRNA＋TRAIL组的抑制率（%）分别为（60.27±1.25）、（11.34±1.74）及（74.91±2.12）。对比阴性对照组的凋亡率（3.12±1.54）,TRAIL组（12.79±2.46）和c-FLIP-siRNA＋TRAIL组（25.50±3.17）组的凋亡率明显增高（P〈0.05）,c-FLIP-siRNA组（6.85±2.82）的凋亡率变化不明显,差异无统计学意义（P〉0.05）。结论：siRNA抑制c-FLIP基因的表达能显著促进TRAIL对乳腺癌细胞MCF-7凋亡的诱导作用。     

槲皮素对乳腺癌MCF-7和MDA-MB-435细胞的凋亡作用及机制研究

摘要 目的：探讨槲皮素对乳腺癌MCF-7和MDA-MB-435细胞的凋亡作用,并探讨其作用机制。方法：采用活细胞计数法(CCK-8)测定槲皮素对乳腺癌MCF-7和MDA-MB-435细胞增殖的作用,分别采用细胞划痕实验和Transwell实验测定槲皮素对乳腺癌MCF-7和MDA-MB-435细胞迁移和侵袭的影响,采用流式细胞术测定槲皮素对乳腺癌MCF-7和MDA-MB-435细胞凋亡的作用,采用实时荧光定量聚合酶链反应(qRT-PCR)和免疫印迹法(West-blotting)测定槲皮素对乳腺癌MCF-7和MDA-MB-435细胞Fas、FasL、Bcl-2和Bax mRNA和蛋白表达的影响。结果：槲皮素（50~200 μmol/L）作用乳腺癌MCF-7和MDA-MB-435细胞 24 h、48 h和72 h对其增殖具有显著的抑制作用,并且呈浓度依赖性（P<0.05）;细胞划痕实验中槲皮素50 μmol/L和100 μmol/L可使乳腺癌MCF-7和MDA-MB-435细胞划痕宽度较对照组显著增加（P<0.05）;Transwell试验中槲皮素50 μmol/L和100 μmol/L可使乳腺癌MCF-7和MDA-MB-435穿膜细胞较对照组显著降低（P<0.05）;槲皮素50 μmol/L和100 μmol/L可使乳腺癌MCF-7和MDA-MB-435细胞凋亡率较对照组显著升高（P<0.05）;槲皮素50 μmol/L和100 μmol/L可使乳腺癌MCF-7和MDA-MB-435细胞中Bcl-2 mRNA表达较对照组显著降低（P<0.05）,Fas、FasL和Bax mRNA表达较对照组显著升高（P<0.05）;槲皮素50 μmol/L和100 μmol/L可使乳腺癌MCF-7和MDA-MB-435细胞中Bcl-2 蛋白表达较对照组显著降低（P<0.05）,Fas、FasL和Bax 蛋白表达较对照组显著升高（P<0.05）。结论：槲皮素可促进乳腺癌细胞的凋亡,可能与其通过作用Fas/FasL凋亡信号通路而激活外源性凋亡途径,通过作用Bcl-2凋亡信号通路而激活内源性凋亡途径有关。     

脱氧核酶抑制Akt1基因对MCF-7乳腺癌细胞生长的影响

目的应用脱氧核酶抑制Akt1的表达,观察MCF-7乳腺癌细胞生长及凋亡情况。方法采用噻唑蓝比色法（MTT）检测脱氧核酶抑制MCF-7乳腺癌细胞增殖作用;DAPI染色法分析细胞凋亡形态学的变化;流式细胞术检测脱氧核酶对MCF-7乳腺癌细胞凋亡的影响;运用蛋白免疫印迹检测分析Akt1、pro—caspase-3、pro-caspase-9的变化。结果Aktl脱氧核酶对MCF-7乳腺癌细胞在体外的生长具有抑制作用;DRz1组的细胞早期凋亡率显著高于未处理组;荧光显微镜下可见典型的凋亡形态学变化;脱氧核酶作用后,免疫印迹检测Aktl蛋白表达降低,pro—caspase-3、9均被活化。结论AktlDRzl能有效下调MCF-7乳腺癌细胞Akt1的蛋白表达水平,抑制MCF-7细胞的生长,且凋亡途径可能依赖于caspase-3、9的相关的线粒体凋亡途径。     

miR-486-3p对乳腺癌细胞MCF-7凋亡的调控作用研究

为探讨miR-486-3p对乳腺癌细胞MCF-7凋亡的调控作用,采用qRT-PCR法和Western blot法测定24例乳腺癌组织和癌旁正常组织miR-486-3p和凋亡相关蛋白的表达水平;采用qRT-PCR法测定乳腺癌细胞MCF-7、HBL101和正常乳腺细胞MCF10A中miR-486-3p的表达水平。将MCF-7、HBL101和MCF10A细胞分为正常对照组、模拟物对照组、miR-486-3p模拟物组、抑制物对照组和miR-486-3p抑制物组,各组细胞转染后进行培养,采用CCK-8法测定各组细胞增殖情况,采用细胞划痕法测定MCF-7和MCF10A细胞的迁移情况,采用Transwell法和流式细胞术测定各组细胞侵袭和凋亡情况,采用qRT-PCR和Western blot法测定凋亡相关蛋白mRNA和蛋白的表达水平。该研究得出乳腺癌组织中miR-486-3p表达水平较癌旁正常组织显著降低(P0.05),乳腺癌组织中Bcl-2蛋白表达水平较癌旁正常组织显著增加(P0.05),而Bax和Caspase-3蛋白表达水平较癌旁正常组织显著降低(P0.05)。乳腺癌细胞MCF-7和HBL101中miR-486-3p表达水平较正常乳腺细胞MCF10A显著降低(P0.05),其中以乳腺癌细胞MCF-7中miR-486-3p表达水平最低。miR-486-3p模拟物组乳腺癌细胞MCF-7和HBL101中miR-486-3p的表达水平较模拟物对照组显著升高(P0.05),miR-486-3p抑制物组miR-486-3p的表达水平较抑制物对照组显著降低(P0.05)。miR-486-3p模拟剂组乳腺癌MCF-7和HBL101细胞在24 h、48 h和72 h时的吸光度值较模拟物对照组显著降低(P0.05),而miR-486-3p抑制物组在24 h、48 h和72 h时吸光度值较抑制物对照组显著升高(P0.05)。miR-486-3p模拟剂组乳腺癌MCF-7细胞划痕宽度显著宽于模拟物对照组(P0.05),而miR-486-3p抑制物组乳腺癌MCF-7细胞划痕宽度显著窄于抑制物对照组(P0.05)。miR-486-3p模拟剂组乳腺癌MCF-7细胞穿膜细胞数量较模拟剂对照组显著降低(P0.05),而miR-486-3p抑制物组穿膜细胞数量较抑制物对照组显著升高(P0.05)。miR-486-3p模拟剂组乳腺癌MCF-7细胞凋亡数量较模拟物对照组显著升高(P0.05),而miR-486-3p抑制物组细胞凋亡数量较抑制物对照组显著降低(P0.05)。miR-486-3p模拟剂组乳腺癌MCF-7细胞中Bcl-2 mRNA和蛋白表达水平较模拟物对照组显著降低(P0.05),Bax和Caspase-3表达水平显著升高(P0.05),miR-486-3p抑制物组Bcl-2表达水平较抑制物对照组显著升高(P0.05),Bax和Caspase-3表达水平显著降低(P0.05)。总之,miR-486-3p是乳腺癌的抑癌基因,可能通过调节凋亡相关蛋白Bcl-2、Bax和Caspase-3 mRNA及蛋白的表达,而对乳腺癌细胞的凋亡起促进作用。     

全反式维甲酸联合替莫唑胺对胶质瘤U251细胞增殖与凋亡的影响

目的：研究全反式维甲酸（ATRA）联合替莫唑胺（TMZ）对胶质瘤细胞株U251增殖及凋亡的影响。方法：体外培养胶质瘤细胞株U251,分为ATRA组、TMZ组、ATRA＋TMZ组和空白对照4组,应用MTT法测定U251细胞生长抑制率,流式细胞仪检测细胞周期分布和细胞凋亡率,westernblot法检测细胞维甲酸受体β（RARβ）蛋白和凋亡相关蛋白Caspase．3蛋白的表达情况。结果：对照组、ATRA组、TMZ组及ATRA＋TMZ组的细胞生长抑制率分别为（1．72±0．12）％、（9．87±0．87）％、（23．87＋1．32）％及（35．74±1．44）％,ATRA＋TMZ组的细胞生长抑制率显著高于单独应用TMZ（P〈0．01）。对照组、ATRA组、TMZ组及ATRA＋TMZ组的细胞凋亡率分别为（1．32±0．11）％、（4．16±0．35）％、（8．44±0149）％、（15．27±1．03）％,ATRA＋TMZ组的凋亡率显著高于单独应用TMZ有更高的凋亡率（P〈0．01）。对照组、ATRA组、TMZ组及ATRA＋TMZ组RARp蛋白相对表达量分别0．452±0．054、0．837±0．068、0．195±0．021、0．376±0．039,ATRA＋TMZ组RARβ蛋白相对表达量显著高于TMZ组（P〈0．01）。ATRA＋TMZ组Caspase．的3蛋白表达相对水平为（0．832±0．059）,明显高于ATRA组（0．334±0．041）及TMZ组（0．521＋0．032）,差异具有统计学意义（P〈0．01）。结论：全反式维甲酸联合替莫唑胺能更有效抑制U251细胞的增殖,增加其凋亡率,这可能与其增加RARβ和Caspase-3蛋白的表达抑制U251细胞增殖、诱导细胞凋亡有关。     

Suberoylanilide Hydroxamic Acid,an Inhibitor of Histone Deacetylase,Enhances Radiosensitivity and Suppresses Lung Metastasis in Breast Cancer In Vitro and In Vivo

Triple-negative breast cancer (TNBC), defined by the absence of an estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, is associated with an early recurrence of disease and poor outcome. Furthermore, the majority of deaths in breast cancer patients are from metastases instead of from primary tumors. In this study, MCF-7 (an estrogen receptor-positive human breast cancer cell line), MDA-MB-231 (a human TNBC cell line) and 4T1 (a mouse TNBC cell line) were used to investigate the anti-cancer effects of ionizing radiation (IR) combined with suberoylanilide hydroxamic acid (SAHA, an inhibitor of histone deacetylase (HDAC)) and to determine the underlying mechanisms of these effects in vitro and in vivo. We also evaluated the ability of SAHA to inhibit the metastasis of 4T1 cells. We found that IR combined with SAHA showed increased therapeutic efficacy when compared with either treatment alone in MCF-7, MDA-MB-231 and 4T1 cells. Moreover, the combined treatment enhanced DNA damage through the inhibition of DNA repair proteins. The combined treatment was induced primarily through autophagy and ER stress. In an orthotopic breast cancer mouse model, the combination treatment showed a greater inhibition of tumor growth. In addition, SAHA inhibited the migration and invasion abilities of 4T1 cells and inhibited breast cancer cell migration by inhibiting the activity of MMP-9. In an in vivo experimental metastasis mouse model, SAHA significantly inhibited lung metastasis. SAHA not only enhances radiosensitivity but also suppresses lung metastasis in breast cancer. These novel findings suggest that SAHA alone or combined with IR could serve as a potential therapeutic strategy for breast cancer.     

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

Acetylation of histones leads to conformational changes of DNA. We have previously shown that the histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA), induced cell cycle arrest, differentiation, and apoptosis. In addition to their antitumor effects as single agents, HDAC inhibitors may cause conformational changes in the chromatin, rendering the DNA more vulnerable to DNA damaging agents. We examined the effects of SAHA on cell death induced by topo II inhibitors in breast cancer cell lines. Topo II inhibitors stabilize the topo II-DNA complex, resulting in DNA damage. Treatment of cells with SAHA promoted chromatin decondensation associated with increased nuclear concentration and DNA binding of the topo II inhibitor and subsequent potentiation of DNA damage. While SAHA-induced histone hyperacetylation occurred as early as 4 h, chromatin decondensation was most profound at 48 h. SAHA-induced potentiation of topo II inhibitors was sequence-specific. Pre-exposure of cells to SAHA for 48 h was synergistic, whereas shorter pre-exposure periods abrogated synergy and exposure of cells to SAHA after the topo II inhibitor resulted in antagonistic effects. Synergy was not observed in cells with depleted topo II levels. These effects were not limited to specific types of topo II inhibitors. We propose that SAHA significantly potentiates the DNA damage induced by topo II inhibitors; however, synergy is dependent on the sequence of drug administration and the expression of the target. These findings may impact the clinical development of combining HDAC inhibitors with DNA damaging agents.     

Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids

All-trans retinoic acid (ATRA) can down regulate the anti-apoptotic protein Bcl-2 and the cell cycle proteins cyclin D1 and cdk2 in estrogen receptor-positive breast cancer cells. We show here that retinoids can also reduce expression of the inhibitor of apoptosis protein, survivin. Here we have compared the regulation of these proteins in MCF-7 and ZR-75 breast cancer cells by natural and synthetic retinoids selective for the RA receptors (RARs) alpha, beta, and gamma then correlated these with growth inhibition, induction of apoptosis and chemosensitization to Taxol. In both cell lines ATRA and 9-cis RA induced the most profound decreases in cyclin D1 and cdk2 expression and also mediated the largest growth inhibition. The RARalpha agonist, Ro 40-6055 also strongly downregulated these proteins although did not produce an equivalent decrease in S-phase cells. Only ATRA induced RARbeta expression. ATRA, 9-cis RA and 4-HPR initiated the highest level of apoptosis as determined by mitochondrial Bax translocation, while only ATRA and 9-cis RA strongly reduced Bcl-2 and survivin protein expression. Enumeration of dead cells over 96 h correlated well with downregulation of both survivin and Bcl-2. Simultaneous retinoid-mediated reduction of both these proteins also predicted optimal Taxol sensitization. 4-HPR was much weaker than the natural retinoids with respect to Taxol sensitization, consistent with the proposed requirement for reduced Bcl-2 in this synergy. Neither the extent of cell cycle protein regulation nor AP-1 inhibition fully predicted the antiproliferative effect of the synthetic retinoids suggesting that growth inhibition requires regulation of a spectrum of RAR-regulated gene products in addition even to pivotal cell cycle proteins.     

The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells

Doxorubicin (Adriamycin) is the most active drug in the treatment of breast cancer. The aim of this study was to investigate the interaction of doxorubicin and retinoids in the inhibition of proliferation of hormone sensitive (ER+) human breast cancer cell line MCF-7 and to find out whether this combination can result in the enhancement of its therapeutic effect. As a comparison we also used estradiol and tamoxifen. We also made an attempt to elucidate the effect of these compounds on the stimulation of the apoptotic pathway in breast cancer cells. Cell proliferation in a 24-hour culture was assessed by [3H] thymidine incorporation into cancer cells and by immunocytochemical analysis of cellular cycle-related PCNA and Ki-67 antigens expression, after the incubation of the cell culture with 10, 20 and 50 nM doxorubicin (DOX), 2 nM estradiol (E2), 10 microM tamoxifen (TAM) and 1 nM, 0.01, 0.1, 1 and 10 microM of all-trans retinoid acid (ATRA). The assessment of cell viability and analysis of apoptotic and necrotic cells were performed after the 72-hour incubation of the culture with the examined substances and following apoptosis induction using acridine orange and ethidine bromide. Of the doxorubicin concentrations used in the study, 20 nM inhibited thymidine incorporation to 84.83 +/- 10.00% (control=100%). In the same culture conditions, 2 nM E2 stimulated cancer cells to 157.09 +/- 8.84%. Concentrations of 10 microM TAM and 10 microM ATRA inhibited the proliferation to 63.16 +/- 7.85% and 52.19 +/- 3.21%, respectively. A statistically significant reduction of these values was observed when 20 nM DOX was added to medium with E2 - 39.24 +/- 7.6%, TAM - 48.34 +/- 2.05% and ATRA - 21.98 +/- 1.69%, respectively; the percentage of PCNA- and Ki-67-positive cells was also reduced. Despite high antiproliferative efficacy of 20 nM DOX and 10 microM ATRA combination, the percentage of apoptotic cells was only 25 +/- 0.81%, being similar to that obtained in the culture with 20 nM DOX. The concentrations of 10, 20 and 50 nM DOX that were used to inhibit the proliferation of MCF-7 cell line were not particulary effective. The inhibitory effect was obtained when 20 nM of DOX and E2, TAM or ATRA were used simultaneously. The use of E2 caused a two-fold decrease in the percentage of proliferating cells. It was also shown that the effectiveness of DOX in combination with ATRA is significantly higher than that of DOX combined with TAM, which might suggest a valuable approach to the treatment of breast cancer.     

RNA干扰NUP88基因对人乳腺癌MCF-7细胞生长及侵袭力的影响

目的： 构建重组慢病毒介导的NUP88-shRNA载体,通过RNAi技术分别观察沉默NUP88后对MCF-7增殖,粘附,侵袭和转移情况的影响,为乳腺癌的临床基因治疗寻找新的靶点。方法： 构建NUP88重组慢病毒表达载体,包装后检测滴度,以最佳复感染指数转染乳腺癌MCF-7细胞,利用RT-PCR和Western blot检测各组MCF-7细胞中mRNA和蛋白的表达效率;MTT法和流式细胞仪检测法,检测NUP88基因被干扰后对MCF-7细胞增殖和凋亡的影响;细胞侵袭实验检测NUP88基因被干扰后对MCF-7侵袭力的影响。结果 四组病毒及一组阴性对照均构建成功,滴度均为4E+8TU/ml;RT-PCR和Western blot检测,结果表明：经NUP88-shRNA转染的MCF-7细胞组NUP88 mRNA和蛋白质的表达与经阴性转染组和空白MCF-7细胞组相比,差异明显具有统计学意义（P<0.01）;测定NUP88-shRNA1组沉默效率最高,沉默率可达到86%;MTT法结果表明：实验组经NUP88-shRNA1慢病毒转染后细胞增殖程度显著减少,与空白组和对照组相比有显著性差异（P<0.05）。流式细胞仪检测三组MCF-7细胞凋亡结果表明：实验组经慢病毒转染后细胞凋亡率显著增加,与对照组和空白组相比有显著性差异（P<0.05）;细胞侵袭实验表明：在肿瘤细胞常规培养24h后,实验组与空白组和阴性对照组比较,穿膜细胞数量明显减少,具有显著性差异（P<0.05） 结论： NUP88重组慢病毒可以通过RNAi成功抑制MCF-7中NUP88基因的表达,并能显著抑制其增殖及远处的侵袭能力。     

藻蓝蛋白联合全反式维甲酸对HeLa细胞生长抑制作用的研究(英文)

目的:探讨全反式维甲酸和藻蓝蛋白单独及联合用药对HeLa细胞生长的影响,并揭示两者联合用药对细胞周期和细胞凋亡影响的分子机制。方法:MTT法检测全反式维甲酸和藻蓝蛋白单独及联合用药对HeLa细胞生长的影响,原位杂交法检测用药前后细胞内CDK-4基因mRNA的表达情况,免疫组化法检测用药前后bcl-2基因的表达情况,TUNEL法检测用药前后细胞凋亡情况。结果:全反式维甲酸和藻蓝蛋白均具有抑制HeLa细胞生长的作用,当达到相同的抑制率时,联合藻蓝蛋白使用可以显著降低全反式维甲酸的使用剂量从而达到降低毒副作用的目的。两者联合用药可以显著降低CDK-4的表达量从而对HeLa细胞的细胞周期产生影响。两者联合用药可以显著下调bcl-2的表达水平从而引发细胞凋亡。结论:通过联合藻蓝蛋白,可以显著降低全反式维甲酸的使用剂量从而降低毒副作用。全反式维甲酸和藻蓝蛋白联合用药抑制HeLa细胞生长的分子机制可能是通过抑制CDK-4和bcl-2的表达来影响细胞周期并最终导致细胞凋亡。